Improving efficiency and value in health care. Intravenous iron management for anaemia associated with chronic kidney disease: linking treatment to an outpatient clinic, optimizing service provision and patient choice - PubMed (original) (raw)
Improving efficiency and value in health care. Intravenous iron management for anaemia associated with chronic kidney disease: linking treatment to an outpatient clinic, optimizing service provision and patient choice
Sunil Bhandari et al. J Eval Clin Pract. 2008 Dec.
Abstract
Rationale: The National Service Framework advocates correction of anaemia in patients with chronic kidney disease (CKD). Oral iron is insufficient, while intravenous (IV) supplementation replenishes and maintains iron stores. In Yorkshire numerous peripheral clinics exist to reduce travel for patients, but patients must travel to the main unit for IV iron therapy. Therefore an outpatient service in tandem with a routine clinic for administration of IV CosmoFer was created.
Purpose: To evaluate the feasibility and benefits of IV iron therapy in the outpatient clinic during active patient review for CKD patients.
Design: A cross-sectional study of patients attending for total dose IV iron (n = 57) at a peripheral clinic. Iron was administered and monitored according to protocol by one of the clinic nurses with medical staff available in the adjoining room. Haemoglobin, ferritin and renal function were recorded pre-infusion and after 4-6 months. Results are given as medians/means +/- standard error.
Results: A total of 76 IV infusions were carried out with no reported side effects or haemodynamic instability. Haemoglobin (median 10.9 vs. 11.3 g dL(-1), P = NS), creatinine and estimated glomerular filtration rate (eGFR) over the 6-month period remained stable. Serum ferritin rose significantly [80.9 +/- 6.2 vs. 186.4 +/- 18.2 g L(-1) (P < 0.001)]. Hospital time saved 380 day case bed hours, doctor hours saved 76 hours, and patient hours saved 3 hours/patient. Cost savings for TDI CosmoFer in peripheral clinic versus in centre therapy and versus sucrose, respectively, for 76 treatments was pound 5749.40 and pound 46,320.80 respectively.
Conclusion: We have demonstrated, in a resource-limited service, the feasibility and cost-effectiveness of a management care pathway for patients with CKD, in a peripheral clinic, to receive total dose IV CosmoFer without disruption of a functioning renal clinic.
Similar articles
- Comparison of intravenous iron sucrose versus low-molecular-weight iron dextran in chronic kidney disease.
Sinha S, Chiu DY, Peebles G, Kolakkat S, Lamerton E, Fenwick S, Kalra PA. Sinha S, et al. J Ren Care. 2009 Jun;35(2):67-73. doi: 10.1111/j.1755-6686.2009.00099.x. J Ren Care. 2009. PMID: 19432851 - Intravenous iron supplementation for the treatment of anaemia in pre-dialyzed chronic renal failure patients.
Mircescu G, Gârneata L, Capusa C, Ursea N. Mircescu G, et al. Nephrol Dial Transplant. 2006 Jan;21(1):120-4. doi: 10.1093/ndt/gfi087. Epub 2005 Sep 6. Nephrol Dial Transplant. 2006. PMID: 16144853 Clinical Trial. - Intravenous iron in chronic kidney disease: haemoglobin change shortly after treatment of patients neither on dialysis nor on erythropoietin.
Tagboto S, Cropper L, Mostafa S, Turner J, Bailey G, Pugh-Clarke K. Tagboto S, et al. J Ren Care. 2008 Sep;34(3):112-5. doi: 10.1111/j.1755-6686.2008.00026.x. J Ren Care. 2008. PMID: 18786076 Clinical Trial. - IV iron use in patients with higher serum ferritin: case study on anemia in kidney disease.
Larson K. Larson K. Nephrol Nurs J. 2008 Mar-Apr;35(2):184-93; quiz 194-5. Nephrol Nurs J. 2008. PMID: 18472686 Review. - The efficacy and safety of current intravenous iron preparations for the management of iron-deficiency anaemia: a review.
Qunibi WY. Qunibi WY. Arzneimittelforschung. 2010;60(6a):399-412. doi: 10.1055/s-0031-1296304. Arzneimittelforschung. 2010. PMID: 20648931 Review.
Cited by
- Treatment of Iron Deficiency Anemia in CKD and End-Stage Kidney Disease.
Gutiérrez OM. Gutiérrez OM. Kidney Int Rep. 2021 Jun 5;6(9):2261-2269. doi: 10.1016/j.ekir.2021.05.020. eCollection 2021 Sep. Kidney Int Rep. 2021. PMID: 34514189 Free PMC article. Review. - Beyond efficacy and safety-the need for convenient and cost-effective iron therapy in health care.
Bhandari S. Bhandari S. NDT Plus. 2011 Jun;4(Suppl 1):i14-i19. doi: 10.1093/ndtplus/sfr044. NDT Plus. 2011. PMID: 27045221 Free PMC article. - Efficacy and safety of iron isomaltoside (Monofer(®)) in the management of patients with iron deficiency anemia.
Kalra PA, Bhandari S. Kalra PA, et al. Int J Nephrol Renovasc Dis. 2016 Mar 10;9:53-64. doi: 10.2147/IJNRD.S89704. eCollection 2016. Int J Nephrol Renovasc Dis. 2016. PMID: 27022297 Free PMC article. Review. - The safety of accelerated infusion versus standard rate infusion of low-molecular-weight iron dextran in patients with chronic kidney disease.
Sinha S, Chiu DY, Peebles G, Kolakkat S, Lamerton E, Fenwick S, Kalra PA. Sinha S, et al. NDT Plus. 2009 Oct;2(5):432-3. doi: 10.1093/ndtplus/sfp073. NDT Plus. 2009. PMID: 25949371 Free PMC article. No abstract available.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous